1 Profitable Stock to Target This Week and 2 We Avoid
This article identifies one profitable stock, Elevance Health (ELV), as a company to target due to its consistent revenue growth, large revenue base, and strong return on capital. Conversely, it advises avoiding Fastenal (FAST) and Bio-Techne (TECH) due to their muted revenue and earnings growth, high valuations, and in Bio-Techne's case, subscale operations and shrinking free cash flow margin. The analysis emphasizes looking beyond profitability to growth and operational efficiency when evaluating investment opportunities.
Bio-Techne Corp (TECH): Investor Outlook Highlights 25.56% Potential Upside with Strong Buy Ratings
Bio-Techne Corp (NASDAQ: TECH), a biotechnology company specializing in life science reagents, instruments, and services, has a market cap of $9.38 billion. The company shows a positive EPS of 0.53 and a 0.53% dividend yield, despite a slight revenue decline. Analysts are overwhelmingly positive, with 11 buy ratings and no sell ratings, projecting a 25.56% potential upside with an average target price of $75.25.
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge?Based Immunoassays for European Clinical Laboratories
Bio-Techne has announced that its Ella benchtop immunoassay platform has received CE-IVD marking, making it available for sale in the European Union. This certification allows European clinical laboratories to utilize Ella for in-house test development, clinical trials, and translational activities, streamlining workflows and enhancing diagnostic capabilities with its rapid, reproducible, and minimal hands-on immunoassay system. The platform, compatible with Simple Plex assays for research use, aims to improve clinical decision-making and patient outcomes in various scientific investigations.
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge?Based Immunoassays for European Clinical Laboratories
Bio-Techne's Ella immunoassay platform has received CE-IVD marking, making it available for sale in the European Union. This certification allows European clinical laboratories to use Ella for in-house test development, clinical trials, and translational activities, streamlining workflows and supporting timely decision-making. The Ella system provides rapid, reproducible biomarker results in under 90 minutes, enhancing precision diagnostics and patient outcomes.
Bio-Techne Corp's Ella platform receives CE-IVD marking, available for sale in EU
Bio-Techne Corporation's Ella platform has received CE-IVD marking, making it available for sale in the European Union. This regulatory approval will allow the company to expand its market presence and offer its diagnostic and analytical tools to research and medical facilities across the EU. The article also touches on recent leadership changes and analyst ratings for Bio-Techne.
Bio-Techne's Ella Platform Receives CE-IVD Marking
Bio-Techne's Ella platform has secured CE-IVD marking, enabling its sale and use in the EU for precision diagnostics. This platform provides rapid, accurate biomarker results in under 90 minutes, supporting clinical decision-making and compatible with over 390 analytes across neuroscience, immunology, and oncology. The certification reinforces Bio-Techne's commitment to advancing precision medicine through reliable and standardized biomarker detection solutions.
Bio-Techne Corp's Ella Platform Receives CE-Ivd Marking, Available For Sale In EU
Bio-Techne Corporation's Ella Platform has officially received CE-IVD marking, which designates the product as compliant with European in vitro diagnostic medical device regulations. This certification makes the Ella Platform available for sale and use in the European Union.
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
Bio-Techne's Ella immunoassay platform has received CE-IVD marking, enabling its sale and use in the European Union for clinical laboratories. This compact, cartridge-based system provides rapid, reproducible biomarker results in under 90 minutes. The certification allows hospitals and labs to use Ella for in-house test development, clinical trials, and other translational activities, enhancing precision diagnostics.
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
Bio-Techne's Ella benchtop immunoassay platform has received CE-IVD marking, allowing its sale and use in clinical laboratories across the European Union. This certification enables hospitals and labs to utilize Ella for in-house test development and clinical trials, providing rapid, cartridge-based biomarker results in under 90 minutes. While the Ella platform is CE-IVD marked, its Simple Plex assays remain for research use only, requiring developers to build specific clinical applications on the validated system.
ING Groep NV Acquires Shares of 20,266 Bio-Techne Corp $TECH
ING Groep NV has acquired a new position in Bio-Techne Corp (NASDAQ:TECH), purchasing 20,266 shares valued at approximately $1,127,000 in the third quarter. This move is part of broader institutional interest, with several hedge funds modifying their holdings in the biotechnology company. Analysts have issued various ratings for Bio-Techne, resulting in an average "Moderate Buy" rating and a target price of $72.77.
Caprock Group LLC Takes $1.71 Million Position in Bio-Techne Corp $TECH
Caprock Group LLC has acquired a new position in Bio-Techne Corp (NASDAQ:TECH), purchasing 31,302 shares valued at approximately $1.71 million during the third quarter. This move further solidifies institutional ownership, which now stands at nearly 99% of the company's stock. Bio-Techne recently surpassed earnings and revenue expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $72.77.
Principal Financial Group Inc. Sells 35,059 Shares of Bio-Techne Corp $TECH
Principal Financial Group Inc. reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 17.2% in the third quarter, selling 35,059 shares and retaining 168,801 shares valued at $9.39 million. While Bio-Techne slightly beat Q4 EPS estimates, its revenue declined year-over-year, raising analyst concerns given its high P/E ratio. The company declared a quarterly dividend of $0.08 and announced a leadership transition in its Diagnostics & Spatial Biology division.
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Bio-Techne Corporation's recent earnings report, despite appearing lackluster, may be stronger than it seems due to a significant US$155m expense attributed to unusual, likely one-off, items. Removing the impact of these unusual items suggests Bio-Techne's underlying earnings potential is better than its statutory profit indicates. The article emphasizes that investors should look beyond the reported earnings to understand the company's true financial health.
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Bio-Techne Corporation (NASDAQ:TECH) recently reported earnings that were weaker than expected due to a significant US$155m expense classified as an "unusual item." Simply Wall St analysis suggests that despite the statutory profit being lower, the underlying earnings potential of the company might be stronger than it appears, as these unusual items are typically one-off. Investors are encouraged to look beyond the reported profit and consider other factors like margins, growth forecasts, and return on investment while being aware of the associated risks.
Standard BioTools Inc.'s (NASDAQ:LAB) Popularity With Investors Under Threat As Stock Sinks 27%
Standard BioTools Inc. (NASDAQ:LAB) has seen its stock drop 27% in the last month, contributing to an 11% decline over the past year. Despite a strong prior revenue growth of 80% last year and 55% over three years, analysts predict a 21% annual revenue decline for the next three years, contrasting with an expected 7.7% industry growth. This raises concerns about the company's price-to-sales ratio, which is currently similar to the industry median, suggesting investors might be overlooking future revenue declines.
5 Insightful Analyst Questions From Bio-Techne's Q4 Earnings Call
Bio-Techne exceeded Q4 expectations with flat revenue, driven by strong pharmaceutical customer demand despite cell therapy headwinds. Management confirmed mid-single-digit growth is anticipated as conditions normalize, with strategic focus on higher-margin products and M&A in antibodies and cell therapy. Analysts probed deeper into growth cadence, margin recovery drivers, and the timing of biotech funding impact on revenue.
What Are Wall Street Analysts' Target Price for Bio-Techne Stock?
Bio-Techne Corporation (TECH) has underperformed the broader market and the iShares Biotechnology ETF over the past 52 weeks, but has shown stronger performance year-to-date and recently surpassed Q2 earnings estimates. Analysts have a "Moderate Buy" consensus rating for TECH, with Wells Fargo setting a price target of $76, indicating a potential upside from current levels. The mean price target for TECH is $74.67, with a Street-high of $80.
Bio-Techne Announces Changes to its Leadership Team
Bio-Techne Corporation (NASDAQ: TECH) announced leadership changes, with Dr. Matt McManus stepping down as President of the Diagnostics and Spatial Biology Segment, effective March 1, 2026. Steve Crouse, currently Senior Vice President of Analytical Solutions, will succeed him. This transition aims to leverage Crouse's extensive experience to drive the company's next phase of growth alongside President of Protein Sciences, Will Geist.
Ex-Dividend Reminder: Bio-Techne, 3M and Eli Lilly
Bio-Techne Corp (TECH), 3M Co (MMM), and Eli Lilly (LLY) are set to trade ex-dividend on February 13, 2026. Bio-Techne will pay a quarterly dividend of $0.08, 3M Co $0.78, and Eli Lilly $1.73. The article highlights the dividend impact on stock prices and provides historical dividend charts for each company.
Bio-Techne Announces Changes to its Leadership Team
Bio-Techne Corporation announced leadership changes, with Dr. Matt McManus transitioning from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed as the new President for the Diagnostics and Spatial Biology Segment. CEO Kim Kelderman thanked Dr. McManus for his contributions and expressed excitement for Crouse’s leadership in driving the company’s next phase of growth.
Bio-Techne Announces Changes to its Leadership Team
Bio-Techne Corporation announced leadership changes, with Dr. Matt McManus transitioning from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Steve Crouse, previously Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed as the new President for the Diagnostics and Spatial Biology Segment. CEO Kim Kelderman expressed gratitude to Dr. McManus for his contributions and enthusiasm for Steve Crouse's leadership in the company's next growth phase.
Bio-Techne Corp (NASDAQ:TECH) Passes Key Quality Investing Screen
Bio-Techne Corp (NASDAQ:TECH) has successfully passed the "Caviar Cruise" quality investing screen, which identifies companies with durable competitive advantages, reliable earnings, and strong financial conditions. The company demonstrates robust earnings growth, effective capital use with a high ROIC, and sound financial strength as indicated by its low Debt-to-Free Cash Flow ratio and high profit quality. While analyst growth expectations are slower, its current valuation is considered workable for quality investors given its strong operational and financial performance.
Baader Bank Aktiengesellschaft Buys 38,082 Shares of Bio-Techne Corp $TECH
Baader Bank Aktiengesellschaft increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 57.9% in the third quarter, acquiring an additional 38,082 shares to hold a total of 103,905 shares valued at $5.78 million. Bio-Techne recently reported better-than-expected earnings of $0.46 EPS on $295.9 million revenue and announced a quarterly dividend of $0.08. Institutional investors own nearly 99% of the stock, and analysts maintain a "Moderate Buy" consensus with an average target price of $72.77.
Azzad Asset Management Inc. ADV Has $774,000 Stock Holdings in Bio-Techne Corp $TECH
Azzad Asset Management Inc. ADV significantly reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 70% in Q3, selling 32,429 shares and retaining 13,913 shares valued at $774,000. Despite this reduction and a high P/E ratio of 128.39, Bio-Techne's Q4 results surpassed expectations, with EPS of $0.46 against an estimated $0.43 and revenue of $295.9 million against $290.2 million. The company announced a quarterly dividend of $0.08 and holds a "Moderate Buy" consensus rating from analysts with a target price of $72.77.
Avantor (AVTR) Reports Q4: Everything You Need To Know Ahead Of Earnings
Avantor (AVTR) is set to announce its Q4 earnings results on Wednesday. Analysts expect Avantor's revenue to decrease by 2.9% year-on-year to $1.64 billion, with adjusted earnings around $0.22 per share. The company has a history of missing Wall Street's revenue estimates and its stock has underperformed the research tools & consumables segment recently.
Exosomes Market to See Thriving Worldwide | Thermo Fisher Scientific, Inc., Bio-Techne
The Exosomes market is projected to grow significantly from US$ 222.1 Mn in 2025 to US$ 1,284.1 Mn by 2032, exhibiting a CAGR of 28.5%. Key players like Thermo Fisher Scientific Inc. and Bio-Techne are driving this expansion through various product types and applications, including emergency air transport and inter-facility transport, catering to end-users such as hospitals and emergency services. The report offers detailed analysis on market structure, competitive dynamics, regional insights across North America, Europe, Asia Pacific, and the Rest of World, identifying growth opportunities and assessing competitive factors.
Bio-Techne stock price target raised to $65 from $60 at Stifel By Investing.com
Stifel has increased its price target for Bio-Techne Corp. (NASDAQ:TECH) to $65 from $60, maintaining a Hold rating. This adjustment follows Bio-Techne's recent quarterly earnings beat, partially due to an earlier-than-expected OEM order. Despite potential flat organic revenue in the fiscal third quarter, the company expects mid-single-digit growth in the fourth quarter and continues to show strong financial health with profitability and good liquidity.
Bio-Techne stock price target raised to $65 from $60 at Stifel
Stifel has raised its price target for Bio-Techne Corp. (NASDAQ:TECH) to $65.00 from $60.00, while maintaining a Hold rating. This increase follows Bio-Techne's second-quarter fiscal year 2026 earnings beat, driven by an OEM order pulled forward into the quarter and strong performance in large pharma and biotech. The company is expected to see flat organic revenue in the fiscal third quarter due to lingering cell therapy headwinds but anticipates a mid-single-digit growth step-up in the fiscal fourth quarter.
Bio-Techne stock price target raised to $65 from $60 at Stifel
Stifel raised its price target on Bio-Techne Corp. (NASDAQ:TECH) to $65 from $60, maintaining a Hold rating. This increase follows Bio-Techne's strong quarterly earnings, benefiting from an pulled-forward OEM order and divestitures, despite some margin pressures. The company also surpassed EPS and revenue forecasts in its Q2 FY26 results.
Comfort Systems USA Inc. (NYSE:FIX): A High-Quality Dividend Growth Stock for Income Investors
Comfort Systems USA Inc. (NYSE:FIX) is identified as a strong candidate for dividend growth investors due to its reliable history of increasing dividends, supported by strong financial health and operational efficiency. The company boasts a low payout ratio of 7.18%, superior returns on capital (ROIC of 32.75%, ROE of 37.50%), and a robust balance sheet with minimal debt. Despite a modest current dividend yield of 0.20% and a high P/E ratio, its consistent growth and financial stability make it an attractive long-term investment for income generation.
Citigroup Raises Price Target for Bio-Techne (TECH) to $80.00
Citigroup has increased its price target for Bio-Techne (TECH) to $80.00, up from $70.00, while maintaining a 'Buy' rating. This adjustment reflects a positive outlook for the company, despite other analysts making varied adjustments to their ratings in recent months. Bio-Techne, a Minnesota-based life sciences manufacturer, supplies consumables and instruments primarily for the pharma, biotech, academic, and diagnostic markets, with significant operations in protein sciences.
Assessing Bio-Techne (TECH) Valuation After Earnings Beat And New Research Product Launches
Bio-Techne (TECH) recently reported an earnings beat, exceeding analyst forecasts due to wider operating margins and new product launches in cell and organoid research tools. Despite positive short-term share price returns and new product introductions, the company's long-term performance has been weaker. Analysts currently value TECH at approximately $70.00, suggesting it is undervalued, supported by a shift in portfolio focus and expected margin improvements.
Evercore ISI Issues Positive Forecast for Bio-Techne (NASDAQ:TECH) Stock Price
Evercore ISI raised its price target for Bio-Techne (NASDAQ:TECH) to $68, maintaining an "in-line" rating despite robust Q2 earnings that surpassed analyst estimates. The biotechnology company's revenue, however, saw a slight year-over-year dip, and its high valuation metrics suggest that significant stock upside may hinge on accelerated revenue growth in the coming fiscal year. Bio-Techne anticipates mid-single-digit underlying growth and margin expansion for FY2026, supported by positive analyst sentiment, though flat organic sales and high valuation present challenges.
TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets
Bio-Techne (NASDAQ:TECH) reported better-than-expected Q4 CY2025 results, with flat revenue but expanded operating margins and a beat on profit estimates. The company's performance was driven by strong growth from large pharmaceutical customers and in the Asia-Pacific region, despite temporary headwinds in cell therapy orders. Management anticipates continued mid-single-digit growth and further margin improvement as market conditions stabilize and product mix normalizes.
TD Cowen Adjusts Price Target on Bio-Techne to $80 From $70, Maintains Buy Rating
TD Cowen has increased its price target for Bio-Techne (NASDAQ:TECH) shares to $80, up from the previous $70, while reiterating a Buy rating on the stock. This adjustment reflects continued positive sentiment from the firm regarding the biotechnology company's future performance. The report was published on February 5, 2026, at 09:52 am EST.
Bio-Techne signals mid-single-digit underlying growth for fiscal 2026, with margin expansion and cell therapy normalization ahead
Bio-Techne is projecting mid-single-digit underlying growth for fiscal year 2026. The company also anticipates margin expansion and a normalization of the cell therapy market, suggesting a positive outlook for future performance.
Citigroup Maintains Buy on Bio-Techne Corporation (TECH) Feb 2026
Citigroup maintained its Buy rating for Bio-Techne Corporation (TECH) on February 4, 2026, and significantly raised its price target from $70 to $80, indicating continued strong confidence in the company's prospects. This decision is based on updated model assumptions, reflecting Bio-Techne's reported mid-single-digit underlying growth and margin expansion in Q2 2026. The maintained Buy rating with an increased price target reinforces a positive outlook for investors, although the stock experienced a slight intraday dip following the announcement.
Bio-Techne Corp Plans Quarterly Dividend of $0.08 (NASDAQ:TECH)
Bio-Techne Corp (NASDAQ:TECH) has announced a quarterly dividend of $0.08 per share, payable on February 27th to shareholders of record by February 16th, with an ex-dividend date of February 13th. The biotechnology company recently beat earnings estimates, reporting $0.46 EPS against an expected $0.43 and $295.9 million in revenue compared to $290.2 million. Analysts maintain a "Moderate Buy" consensus rating for TECH with an average price target of $70.57.
Bio-Techne Releases Second Quarter Fiscal 2026 Results
Bio-Techne reported its second-quarter fiscal 2026 results, with revenue flat at $295.9 million and GAAP EPS at $0.24, up from $0.22 a year ago. The company achieved double-digit growth in large pharma for the fourth consecutive quarter and saw improvements in biotech and academic customers, alongside continued growth in Asia. Bio-Techne celebrates its 50th anniversary, emphasizing a durable and differentiated portfolio in high-growth life sciences.
Bio-Techne (NASDAQ:TECH) Shares Up 7% on Strong Earnings
Bio-Techne (NASDAQ:TECH) shares rose 7% following a better-than-expected earnings announcement for the second quarter of fiscal 2026. The biotechnology company reported EPS of $0.46 against an expected $0.43 and revenue of $295.88 million versus $290.20 million. Despite a slight year-over-year revenue decrease, the company saw an improved operating margin and declared a $0.08 quarterly dividend, maintaining a "Moderate Buy" consensus rating from analysts.
Earnings call transcript: Bio-Techne beats Q2 2026 EPS and revenue forecasts
Bio-Techne Corp (TECH) reported strong second-quarter results for fiscal year 2026, exceeding EPS and revenue forecasts with an EPS of $0.46 and revenue of $295.9 million. Despite flat year-over-year revenue, adjusted EPS grew 10%, driven by product innovation and expansion in China and APAC. The company's stock rose 5.93% in pre-market trading, reflecting investor confidence in its strategic growth verticals and ongoing recovery in key end markets.
Bio-Techne tops forecasts as adjusted EPS climbs 10%
Bio-Techne has exceeded analyst expectations, reporting a 10% increase in adjusted earnings per share. This strong financial performance indicates a positive growth trajectory for the company. The article details its recent financial results, highlighting key metrics.
TECH Q2 Earnings & Revenues Beat Estimates, Operating Margin Up
Bio-Techne Corporation (TECH) reported better-than-expected second-quarter fiscal 2026 results, with adjusted EPS of 46 cents surpassing estimates by 8.2% and revenues of $295.9 million exceeding the Zacks Consensus Estimate by 1.3%. Despite a slight revenue decline and gross margin contraction, the company saw an expansion in its operating margin, increasing 244 basis points to 18.4%. The report highlighted stabilizing U.S. academic and improving biotech markets, strong growth in Asia, and continued robust performance with large pharmaceutical clients.
TECH Q2 Earnings & Revenues Beat Estimates, Operating Margin Up
Bio-Techne Corporation (TECH) reported strong second-quarter fiscal 2026 results, with adjusted EPS of 46 cents surpassing Zacks Consensus Estimate by 8.2% and increasing 9.5% year-over-year. Although net sales saw a marginal decline of 0.4% year over year, they exceeded estimates by 1.3%. The company also achieved a significant expansion in its operating margin, rising 244 basis points to 18.4%.
Bio-Techne (NASDAQ:TECH) Surprises With Q4 CY2025 Sales
Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results, exceeding revenue expectations with $295.9 million in sales, though remaining flat year-on-year. The company's non-GAAP profit per share of $0.46 also surpassed analyst estimates by 5.8%. Despite strong historical growth, recent performance indicates a slowdown in demand, with revenue growth at 3% over the last two years, aligning with organic revenue figures.
Bio-Techne Corp (NASDAQ:TECH) Reports Q2 Earnings Beat, Meets Revenue Forecasts
Bio-Techne Corp (NASDAQ:TECH) reported its Q2 fiscal 2026 financial results, exceeding analyst expectations for non-GAAP EPS ($0.46 vs. $0.4425) and nearly meeting revenue forecasts ($295.88 million vs. $295.99 million). The positive earnings report led to a 2.12% increase in pre-market trading, suggesting a rebound from recent stock declines. The company also declared a quarterly dividend of $0.08 per share and provided analyst estimates for future fiscal periods.
Bio-Techne: Q2 Earnings Insights
Bio-Techne (NASDAQ: TECH) announced its Q2 earnings, beating estimated EPS by 15.0% with a reported EPS of $0.46 against an estimate of $0.4. Despite the earnings beat, revenue for the quarter was down by $1.15 million compared to the previous year. The article also provides a brief overview of the company's past earnings performance over several quarters.
Earnings Flash (TECH) Bio-Techne Corporation Posts Q2 Adjusted EPS $0.46 per Share, vs. FactSet Est of $0.43
Bio-Techne Corporation (TECH) reported its Q2 adjusted EPS of $0.46 per share, surpassing the FactSet estimate of $0.43. This financial news highlights the company's better-than-expected earnings for the quarter.
Bio-Techne Declares Dividend
Bio-Techne Corporation announced its Board of Directors has declared a quarterly dividend of $0.08 per share for the quarter ended December 31, 2025. This dividend will be payable on February 27, 2026, to shareholders of record as of February 16, 2026. Bio-Techne is a global life sciences company that generated over $1.2 billion in net sales in fiscal 2025.
WCM Investment Management LLC Makes New $11.35 Million Investment in Bio-Techne Corp $TECH
WCM Investment Management LLC has acquired a new stake worth $11.35 million in Bio-Techne Corp (NASDAQ:TECH), purchasing 217,380 shares. This investment represents approximately 0.14% of the biotechnology company, which recently reported Q3 EPS of $0.42 and revenue that slightly missed estimates. Institutional investors collectively own 98.95% of Bio-Techne, while analysts hold a "Moderate Buy" consensus rating with a target price of $70.57.
